Policy & Practice

View the latest content related to this topic

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

The combination will be available in several doses and is also approved as a first-line option for patients with hypertension.

Michael O'Riordan

June 10, 2025

Slides

See all

Presentation CTO 2025

Lessons from My First Year(s) in Practice

Presenter: Laura Young

February 28, 2025

Presentation CTO 2025

Lessons from My First Year(s) in Practice

Presenter: Pratik Sandesara

February 28, 2025

Presentation CTO 2025

Lessons from My First Year(s) in Practice

Presenter: Bryan Kindya

February 28, 2025

Presentation Controversies and Advances 2025

The role of double-blind sham-controlled trials in interventional cardiology

Presenter: Rasha Al-Lamee

January 31, 2025

Presentation Controversies and Advances 2025

The Good, the Bad and the Ugly of Clinical Trial Design

Presenter: Stuart Pocock

January 31, 2025

News

See all

News Daily News

Private Equity-Backed Hospitals Appear to 'Cherry-Pick' HF Patients

By Michael O'Riordan

June 16, 2025

News Daily News

Delays in STEMI Treatment Remain Common, Tied to Worse PCI Outcomes

By Todd Neale

June 13, 2025

News Daily News

Majority of US Adults Have High Long-term Risk of CVD: NHANES

By Michael O'Riordan

June 13, 2025

News Daily News

AHA Offers a Primer on Alcohol’s CV Impact, Areas of Uncertainty

By Caitlin E. Cox

June 13, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

By Michael O'Riordan

June 10, 2025

ACC 2025

March 29

March 31, 2025

CTO 2025

February 28

March 01, 2025

THT 2025

February 11

February 13, 2025

Videos on This Topic

See all

Advertisement

Policy & Practice

FDA Approves Triple Therapy Polypill for High Blood Pressure

Slides

Lessons from My First Year(s) in Practice

Lessons from My First Year(s) in Practice

Lessons from My First Year(s) in Practice

The role of double-blind sham-controlled trials in interventional cardiology

The Good, the Bad and the Ugly of Clinical Trial Design

News

Private Equity-Backed Hospitals Appear to 'Cherry-Pick' HF Patients

Delays in STEMI Treatment Remain Common, Tied to Worse PCI Outcomes

Majority of US Adults Have High Long-term Risk of CVD: NHANES

AHA Offers a Primer on Alcohol’s CV Impact, Areas of Uncertainty

FDA Approves Triple Therapy Polypill for High Blood Pressure

More on This Topic

Conference Coverage

ACC 2025

CTO 2025

THT 2025

Videos on This Topic

Advertisement

Policy & Practice

Slides

News

More on This Topic

Conference Coverage

Videos on This Topic

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content